JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

Novartis AG

Fechado

116.79 0.8

Visão Geral

Variação de preço das ações

24h

Atual

Mín

116.52

Máximo

116.9

Indicadores-chave

By Trading Economics

Rendimento

418M

4B

Vendas

660M

14B

P/E

Médio do Setor

16.809

34.393

EPS

2.42

Rendimento de Dividendos

3.46

Margem de lucro

28.18

Funcionários

75,883

EBITDA

-5.8B

4.9M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+5.92% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.46%

2.54%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-11B

228B

Abertura anterior

115.99

Fecho anterior

116.79

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Novartis AG Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de ago. de 2025, 05:47 UTC

Aquisições, Fusões, Aquisições de Empresas

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17 de jul. de 2025, 14:26 UTC

Ganhos

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17 de jul. de 2025, 06:49 UTC

Ganhos

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17 de jul. de 2025, 05:41 UTC

Ganhos

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

8 de ago. de 2025, 11:26 UTC

Conversa de Mercado

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8 de ago. de 2025, 11:07 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8 de ago. de 2025, 10:51 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5 de ago. de 2025, 10:40 UTC

Conversa de Mercado

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17 de jul. de 2025, 11:36 UTC

Conversa de Mercado

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17 de jul. de 2025, 11:26 UTC

Conversa de Mercado

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17 de jul. de 2025, 07:14 UTC

Conversa de Mercado

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17 de jul. de 2025, 07:02 UTC

Conversa de Mercado
Ganhos

Novartis's Results Look Impressive -- Market Talk

17 de jul. de 2025, 05:09 UTC

Ganhos

Novartis 2Q Sales Grew 11% at Constant Currency

17 de jul. de 2025, 05:08 UTC

Ganhos

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17 de jul. de 2025, 05:06 UTC

Ganhos

Novartis: Mehta's Appointment Is Effective March 2026

17 de jul. de 2025, 05:05 UTC

Ganhos

Novartis: Harry Kirsch Retires After 22 Years With Company

17 de jul. de 2025, 05:05 UTC

Ganhos

Novartis Names Mukul Mehta as CFO

17 de jul. de 2025, 05:04 UTC

Ganhos

Analysts Saw Novartis 2Q Net Profit at $3.815B

17 de jul. de 2025, 05:04 UTC

Ganhos

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

17 de jul. de 2025, 05:04 UTC

Ganhos

Analysts Saw Novartis 2Q Sales at $14.17B

17 de jul. de 2025, 05:04 UTC

Ganhos

Novartis 2Q Core Operating Profit $5.925B

17 de jul. de 2025, 05:04 UTC

Ganhos

Novartis 2Q Oper Pft $4.86B

17 de jul. de 2025, 05:03 UTC

Ganhos

Novartis 2Q Sales $14.05B

17 de jul. de 2025, 05:01 UTC

Ganhos

Novartis: Buyback to Be Completed by End of 2027

17 de jul. de 2025, 05:01 UTC

Ganhos

Novartis Starting Buyback of Up to $10B

17 de jul. de 2025, 05:01 UTC

Ganhos

Novartis Backs 2025 Sales View

17 de jul. de 2025, 05:01 UTC

Ganhos

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

17 de jul. de 2025, 05:01 UTC

Ganhos

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

17 de jul. de 2025, 05:00 UTC

Ganhos

Novartis Raises 2025 Earnings View

17 de jul. de 2025, 05:00 UTC

Ganhos

Novartis AG 2Q Adj EPS $2.42

Comparação entre Pares

Variação de preço

Novartis AG Previsão

Preço-alvo

By TipRanks

5.92% parte superior

Previsão para 12 meses

Média 122.78 USD  5.92%

Máximo 137.561 USD

Mínimo 108 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Novartis AG - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

3 ratings

0

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 112.63Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Strong Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.